Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genetic Study in Patients With Stage II or Stage III Colon Cancer

This study has been completed.
NCIC Clinical Trials Group
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: February 6, 2009
Last verified: October 2002

RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer.

PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.

Condition Intervention
Colorectal Cancer
Genetic: DNA stability analysis
Genetic: gene mapping

Study Type: Observational
Official Title: The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: February 1999
Detailed Description:


  • Determine the adverse prognostic significance of 8p allelic imbalance (AI) in patients with colon cancer.
  • Determine if patient prognosis is dependent on the region of 8p AI.
  • Perform fine mapping studies to further localize the putative tumor suppressor gene(s) on 8p.
  • Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI.

OUTLINE: Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.

PROJECTED ACCRUAL: Approximately 480 patients will be accrued for this study.


Ages Eligible for Study:   up to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of resectable stage II or III adenocarcinoma of the colon
  • Participated in NCCTG-914653
  • DNA extracted from both normal and tumor tissue



  • Under 70

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003833

  Hide Study Locations
United States, Minnesota
St. Mary's/Duluth Clinic Health System
Duluth, Minnesota, United States, 55805
Canada, Alberta
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada, T2N 4N2
Lethbridge Cancer Clinic
Lethbridge, Alberta, Canada, T1J 1W5
Canada, British Columbia
Nanaimo Cancer Clinic
Nanaimo, British Columbia, Canada, V9S 2B7
British Columbia Cancer Agency - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada, V3V 1Z2
British Columbia Cancer Agency
Vancouver, British Columbia, Canada, V5Z 4E6
Prostate Centre at Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 3J5
St. Paul's Hospital - Vancouver
Vancouver, British Columbia, Canada, V6Z 1Y6
G. Steinhoff Clinical Research
Victoria, British Columbia, Canada, V8V 3N1
Canada, New Brunswick
Doctor Leon Richard Oncology Centre
Moncton, New Brunswick, Canada, E1C 8X3
Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6ZB
Saint John Regional Hospital
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Newfoundland and Labrador
Newfoundland Cancer Treatment and Research Foundation
St. Johns, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada, B3H 1V7
Cape Breton Cancer Centre
Sydney, Nova Scotia, Canada, B1P 1P3
Canada, Ontario
Royal Victoria Hospital, Barrie
Barrie, Ontario, Canada, L4M 6M2
William Osler Health Centre
Brampton, Ontario, Canada, L6W 2Z8
Hamilton and District Urology Association
Hamilton, Ontario, Canada, L8N 1T8
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5
Markham Stouffville Hospital
Markham, Ontario, Canada, L3P 7T3
Trillium Health Centre
Mississauga, Ontario, Canada, L5B 1B8
Credit Valley Hospital
Mississauga, Ontario, Canada, L5M 2N1
York County Hospital
Newmarket, Ontario, Canada, L3Y 2P9
North York General Hospital, Ontario
North York, Ontario, Canada, M2K 1E1
Male Health Centre/CMX Research Inc.
Oakville, Ontario, Canada, L6H 3PI
Lakeridge Health Oshawa
Oshawa, Ontario, Canada, L1G 2B9
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada, K1H 1C4
Peterborough Oncology Clinic
Peterborough, Ontario, Canada, K9H 7B6
Scarborough Hospital - General Site
Scarborough, Ontario, Canada, M1P 2V5
Hotel Dieu Health Sciences Hospital - Niagara
St. Catharines, Ontario, Canada, L2R 5K3
Northeastern Ontario Regional Cancer Centre, Sudbury
Sudbury, Ontario, Canada, P3E 5J1
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, Canada, P7A 7T1
Saint Joseph's Health Centre - Toronto
Toronto, Ontario, Canada, M6R 1B5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Women's College Campus, Sunnybrook and Women's College Health Science Center
Toronto, Ontario, Canada, M5S 1B6
St. Michael's Hospital - Toronto
Toronto, Ontario, Canada, M5B 1W8
Mount Sinai Hospital - Toronto
Toronto, Ontario, Canada, M5G 1X5
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Toronto East General Hospital
Toronto, Ontario, Canada, M4C 3E7
Humber River Regional Hospital
Weston, Ontario, Canada, M9N 1N8
Cancer Care Ontario - Windsor Regional Cancer Centre
Windsor, Ontario, Canada, N8W 2X3
Canada, Prince Edward Island
Queen Elizabeth Hospital, PEI
Charlottetown, Prince Edward Island, Canada, C1A 8T5
Canada, Quebec
CHUS-Hopital Fleurimont
Fleurimont, Quebec, Canada, J1H 5N4
Hopital Charles Lemoyne
Greenfield Park, Quebec, Canada, J4V 2H1
Centre Hospitalier Regional de Lanaudiere
Joliette, Quebec, Canada, J6E 6J2
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4
Hopital Du Sacre-Coeur de Montreal
Montreal, Quebec, Canada, H4J 1C5
Hopital Sainte Justine
Montreal, Quebec, Canada, H3T 1C5
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, (P.Q.) H2X 3J4
McGill University
Montreal, Quebec, Canada, H2W 1S6
Kells Medical Research Group Inc.
Pointe Claire, Quebec, Canada, H9R 4S3
Centre Hospitalier Universitaire de Quebec
Quebec City, Quebec, Canada, G1R 2J6
Hopital du Saint-Sacrament, Quebec
Quebec City, Quebec, Canada, G1S 4L8
Centre Hospitalier Regional de Rimouski
Rimouski, Quebec, Canada, G5L 5T1
L'Hopital Laval
Ste-Foy, Quebec, Canada, G1V 4G5
Canada, Saskatchewan
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4
Lions Gate Hospital
North Vancouver, Canada, V7L 2P9
Sponsors and Collaborators
North Central Cancer Treatment Group
NCIC Clinical Trials Group
Study Chair: Richard M. Goldberg, MD Mayo Clinic
Study Chair: Lois Shepherd, MD NCIC Clinical Trials Group
  More Information

Additional Information:
No publications provided Identifier: NCT00003833     History of Changes
Other Study ID Numbers: CDR0000066990, NCCTG-984654, CAN-NCIC-CO9PATH
Study First Received: November 1, 1999
Last Updated: February 6, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage II colon cancer
stage III colon cancer
adenocarcinoma of the colon

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases processed this record on November 24, 2014